The committee will discuss new drug application (NDA) 214487, for avacopan oral capsules, submitted by ChemoCentryx, Inc., for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
Back to All Events
Earlier Event: April 27
Oncologic Drugs Advisory Committee
Later Event: May 11
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee